Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coli surface antigen 17 (CS17)
- Target
- CS17
- Molecular classification
- Fimbria, Pilus, Bacterial adhesin, Colonization factor, Class 5b fimbria
01
Overview
Coli surface antigen 17 (CS17) is a fimbrial adhesin classified as a class 5b colonization factor found on the surface of certain enterotoxigenic Escherichia coli (ETEC) strains[1][6][7]. CS17 mediates bacterial attachment to the intestinal mucosa, a critical step for colonization and subsequent diarrheal disease caused by ETEC. It is almost exclusively associated with ETEC strains that produce heat-labile toxin (LT) and is structurally related to other class 5b fimbriae such as CS1, CS19, and PCFO71[7]. CS17 is a possible target for antibody-based therapies and vaccines, as anti-CS17 antibodies can prevent ETEC adhesion and protect against experimental infection[7]. CS17 is primarily of interest in the context of infectious disease rather than as a classical human therapeutic target such as a receptor or enzyme.
- Other names
- Colonization factor antigen CS17CS17 fimbriaColi surface antigen 17ETEC CS17
02
Mechanism of action
Anti-adhesion (blocking binding of ETEC to intestinal cells by targeting CS17 fimbriae) [7]
03
Biological functions
Bacterial adhesion to intestinal epithelial cellsIntestinal colonizationFacilitating infection by enterotoxigenic Escherichia coli (ETEC)
04
Disease associations
Infection (specifically enterotoxigenic Escherichia coli diarrheal disease)
05
Safety considerations
None specifically reported for targeting CS17; challenges are generally related to the variability of fimbriae among ETEC strains and the complexity of generating broad protective immunity [7]
06
Interacting drugs
Hyperimmune bovine colostral anti-CS17 antibody (experimental) [7]
07
Biomarkers
CS17 expression (used for detection of CS17-expressing ETEC in clinical and microbiological surveillance)
Beyond the preview
Go deeper on Coli surface antigen 17 (CS17).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coli surface antigen 17 (CS17).